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SOCS2 is part of a highly prognostic 
4-gene signature in AML and 
promotes disease aggressiveness
Chi Huu Nguyen1,2, Tobias Glüxam1,2, Angela Schlerka1,2, Katharina Bauer1,2,3, 
Alexander M. Grandits1,2, Hubert Hackl  4, Oliver Dovey5, Sabine Zöchbauer-Müller1,2, 
Jonathan L. Cooper5, George S. Vassiliou  5, Dagmar Stoiber6,7, Rotraud Wieser  1,2 & 
Gerwin Heller  1,2,8
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular 
basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients 
into risk groups with different survival, however, within-group heterogeneity is still an issue. Here, we 
used a robust likelihood-based survival modeling approach and publicly available gene expression data 
to identify a minimal number of genes whose combined expression values were prognostic of overall 
survival. The resulting gene expression signature (4-GES) consisted of 4 genes (SOCS2, IL2RA, NPDC1, 
PHGDH), predicted patient survival as an independent prognostic parameter in several cohorts of AML 
patients (total, 1272 patients), and further refined prognostication based on the European Leukemia 
Net classification. An oncogenic role of the top scoring gene in this signature, SOCS2, was investigated 
using MLL-AF9 and Flt3-ITD/NPM1c driven mouse models of AML. SOCS2 promoted leukemogenesis 
as well as the abundance, quiescence, and activity of AML stem cells. Overall, the 4-GES represents 
a highly discriminating prognostic parameter in AML, whose clinical applicability is greatly enhanced 
by its small number of genes. The newly established role of SOCS2 in leukemia aggressiveness and 
stemness raises the possibility that the signature might even be exploitable therapeutically.
Acute myeloid leukemia (AML) is a highly heterogeneous disease in terms of clinical course and outcome: some 
patients do not tolerate, or are refractory to induction chemotherapy, many achieve a remission but go on to 
relapse with frequently therapy resistant disease, while yet others attain a permanent remission and long-term 
survival. AML is organized in a hierarchic manner: leukemic stem cells (LSCs) at the apex of this hierarchy 
give rise to the bulk of the leukemic cells (LCs), exhibit higher resistance to chemotherapy than the latter, and 
represent the cellular source of relapse1. The clinical heterogeneity of AML is related to a number of parameters, 
of which patient age as well as genetic and molecular alterations present in the malignant cells are of particu-
lar importance2–5. Numerous recurrent chromosome aberrations and point mutations have been identified in 
AML, and shown to act as drivers of the disease as well as to have prognostic significance2–6. In addition, AML is 
associated with extensive alterations of the transcriptome, and, like genetic aberrations, changes in gene expres-
sion contribute to leukemogenesis and may represent therapeutic targets3,7–10. With respect to prognostication, 
transcriptional patterns may even outperform the clinical and genetic parameters commonly used for this pur-
pose11. Accordingly, a number of studies have identified gene expression signatures that were associated with 
survival, and in several cases could be cross-validated in additional data sets and even used to refine the European 
Leukemia Net (ELN) score7,12–20, which integrates cytogenetic and mutational information and is the current 
gold standard for prognostication in AML21. However, some of these signatures were established by applying a 
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prior gene selection process that may impede their general applicability, and most contain too many genes to be 
realistically implemented in clinical routine.
Suppressor Of Cytokine Signalling 2 (SOCS2) is transcriptionally activated by JAK-STAT signalling and encodes 
a negative feedback regulator of this pathway, which is aberrantly activated in many cancers including AML22. 
SOCS2 would therefore be predicted to act as a tumor suppressor, and was indeed down-regulated in several types 
of solid tumors22. On the other hand, oncogenic roles of SOCS2 were reported, e.g., in colon and prostate can-
cer23–25. In the healthy murine hematopoietic system, Socs2 was expressed at high levels in stem cells (HSCs) and 
down-regulated during differentiation26,27. A requirement for Socs2 function in HSCs, however, became apparent 
only in specific experimental settings like 5-Fluorouracil treatment or a longer series of consecutive transplan-
tations26,27. As for hematopoietic malignancies, SOCS2 expression was significantly increased in patients with 
chronic myeloid leukemia (CML) in blast crisis as compared to chronic phase patients and healthy controls28, 
but its absence did not alter the latency or histopathologic features of CML like disease in mice transplanted with 
BCR-ABL1 transduced bone marrow cells26. A crucial role of JAK-STAT signalling in AML, including in LSCs, is 
well documented29, but so far, little is known about the role of SOCS2 in this disease.
Here, we report the establishment of a gene expression signature that was composed of 4 genes and consist-
ently associated with survival in 7 cohorts of AML patients with publicly available gene expression and survival 
data. The top gene in this signature was SOCS2. Experiments using mouse models of AML as well as malignant 
human myeloid cell lines demonstrated a role of SOCS2 in disease aggressiveness and stemness.
Results
Establishment of a 4-gene expression signature with prognostic value in AML. Cohort 1 of data 
set GSE12417 was used as training set, because it includes patients of all age groups, but is restricted to AML with 
a normal karyotype, which is the prognostically most heterogeneous of the cytogenetically defined subgroups 
of AML (Table 1)13. After removal of an MDS sample, gene expression data of 162 cytogenetically normal AML 
patients remained for model calculation. A forward gene selection was employed and the optimal prognostic 
model was selected by using the criterion of minimal AIC, an approach to minimize model complexity while 
maintaining maximum fit of the model to the data (Table 2). This approach resulted in the identification of 
4 genes (SOCS2, IL2RA, NPDC1 and PHGDH), whose combined expression values were prognostic of OS in 
this cohort of patients. A 4-gene expression score (4-GES) was calculated using the expression values and the 
β-coefficients from a multivariable Cox regression analysis of each of the 4 genes. Based on the resulting score, 
patients were classified into low risk (N = 60) and high risk (N = 102) groups using maximally selected rank 
statistics (Fig. 1A). Kaplan Meier analysis and log rank testing revealed that AML patients with a high 4-GES 
had significantly shorter OS than patients with a low 4-GES (median survival: 223 days vs. not reached, adjusted 
p = 7.2 * 10−08; Fig. 1B). GSE12417 data were generated using Affymetrix arrays, and on these, many genes are 
Accession number Platform Patients (N)a Ageb Cytogenetics
GSE12417, cohort 1 Affymetrix, HG-U133A 162 58 (17–83) Normal
GSE12417, cohort 2 Affymetrix, HG-U133_Plus_2 78 62 (18–85) Normal
GSE6891, cohort 1 Affymetrix, HG-U133_Plus_2 222 43 (15–60) Heterogeneous
GSE6891, cohort 2 Affymetrix, HG-U133_Plus_2 185 45 (17–60) Heterogeneous
GSE37642 Affymetrix, HG-U133A 379 57 (18–83) Heterogeneous
GSE71014 Illumina HumanHT-12 V4.0 104 na Normal
TCGA_LAML RNA-sequencing 142 60 (18–88) Heterogeneous
Table 1. Summary of AML gene expression data sets retrieved from GEO and TCGA/Cancer Browser 
databases. aNumber of patients after exclusion of samples with FAB M3/unknown FAB type or with MDS. bAge 
in years, median (range). na, not available.
Probe ID
Gene 
Symbol nloglik AIC Selected
203373_at SOCS2 452.01 910.02 *
218086_at NPDC1 449.26 906.52 *
211269_s_at IL2RA 447.91 905.81 *
201397_at PHGDH 444.23 900.46 *
218966_at MYO5C 444.23 902.45
209386_at TM4SF1 443.2 902.39
203372_s_at SOCS2 443.17 904.33
201540_at FHL1 441.85 903.71
211597_s_at HOPX 440.17 902.33
Table 2. Survival associated gene expression model identified by forward gene selection using GSE12417 
cohort 1. Nloglik, negative log likelihood; AIC, Akaike information criterion; AIC is provided for the prognostic 
model including the respective gene and all genes above that gene in the list.
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represented by more than one probe set. The forward selection process used to establish the 4-GES picked only 
one of these per gene. However, all other probe sets for the 4 genes were also prognostic of OS when analysed 
individually (adjusted p < 0.05 in all cases; Supplementary Fig. S1).
In a multivariable setting, the 4-GES remained significantly associated with OS after adjusting for patient age 
(p = 8.8 * 10−08, HR = 3.8; Table 3). The expression pattern of SOCS2, IL2RA, NPDC1, and PHGDH in GSE12417 
cohort 1 is shown in Fig. 1C. Application of the 4-GES to GSE12417 cohort 2, which contains samples from 78 
patients with AML, yielded similar results as described for cohort 1 (p = 0.035, HR = 4.58 after adjusting for age; 
Table 3). Overall, these findings demonstrate that high expression of SOCS2, IL2RA, NPDC1 and PHGDH may 
be of prognostic relevance for AML patients. Thus, we proceeded to validate the model in 5 additional patient 
cohorts.
Validation of the 4-GES in patients with cytogenetically heterogeneous AML. To determine 
whether the 4-GES has prognostic value also in cytogenetically heterogeneous AML, survival analyses were per-
formed using data set GSE6891, which consists of 2 cohorts of AML patients with variable karyotypes30. Because 
treatment of patients with AML M3, characterized by the translocation t(15;17), differs substantially from that of 
all other AML subgroups, the corresponding samples were removed from this and all other cytogenetically het-
erogeneous data sets. The 4-GES again predicted OS in a highly significant manner (adjusted p = 1.2 * 10−05 and 
adjusted p = 5.6 * 10−05 for cohorts 1 and 2, respectively; Fig. 2A,B). In both cohorts, the 4-GES was also signifi-
cant in multivariable analyses including several other prognostic parameters as shown in Table 3. GSE6891 con-
tains information about cytogenetic risk groups. To obtain larger groups, we merged cohorts 1 and 2 and repeated 
survival analyses separately for the three cytogenetic subgroups. A highly significant prognostic value of the 
4-GES was seen for the cytogenetically intermediate subgroup (n = 242, adjusted p = 5.1 * 10−06), but not for the 
substantially smaller cytogenetically favourable (n = 74) and poor (n = 80) subgroups (Supplementary Fig. S2).
The 4-GES is able to refine the ELN risk classification. Like GSE6891, GSE37642 contains data 
from cytogenetically heterogeneous AML16; in addition, ELN risk classification information was available. In 
a first step, the entire study population was divided into a 4-GEShigh (N = 222) and a 4-GESlow (N = 157) group 
(Fig. 3A). Patients in the 4-GEShigh group had significantly shorter OS than patients in the 4-GESlow group 
(adjusted p = 2.1 * 10−12; Fig. 3B). ELN classification was available for 367 patients: 107 were assigned to the 
favourable risk group, 100 to the intermediate I, 74 to the intermediate II, and 86 to the adverse risk group. 
Figure 1. Prognostic value of the 4-GES in 162 cytogenetically normal AML patients (GSE12417, cohort 1). 
(A) Cut-off value for stratification of AML patients into 4-GESlow (blue) and 4-GEShigh (red) was calculated by 
maximally selected rank statistics. (B) Kaplan Meier curves for overall survival of 162 AML patients classified as 
4-GESlow or 4-GEShigh. Log rank tests were calculated and p-values were adjusted for multiple testing according 
to Altman et al.58. (C) Heatmap summarizing expression values of SOCS2, IL2RA, NPDC1 and PHGDH in 
4-GESlow (blue) and 4-GEShigh (red) AML patients. Blue, low expression; red, high expression.
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Multivariable Cox regression analysis revealed that the 4-GES remained significantly associated with OS after 
adjusting for patient age and ELN score (adjusted p = 1.8 * 10−07, HR = 2.13; Table 3). Next, we investigated 
whether the 4-GES was prognostic also within the ELN risk groups. Stratification of the patients within the 
favourable, intermediate I/II, and adverse groups into 4-GEShigh and 4-GESlow subgroups resulted in a clear iden-
tification of patients with shorter OS in the ELN intermediate I/II (adjusted p = 2.6 * 10−07) and adverse (adjusted 
p = 0.027) groups (Fig. 3C). Among the ELN favourable patients, the difference did not reach statistical signifi-
cance after adjustment for multiple testing. To ask whether the 4-GES was able to refine the ELN classification, 
patients from the six groups generated in the previous analysis were combined into three new groups based 
on median survival: ELN favourable/4-GEShigh patients with low median OS were re-assigned to ELN interme-
diate risk group, ELN intermediate/4-GEShigh patients with low median OS were re-assigned to ELN adverse 
risk group, and ELN adverse/4-GESlow patients with high median OS were re-assigned to ELN intermediate risk 
group. The resulting ELN + 4-GES classification indeed substantially refined the ELN score (p = 2.6 * 10−46 vs. 
p = 3 * 10−13 for the ELN + 4-GES and the ELN scores, respectively; Fig. 3D and Supplementary Fig. S3A). Similar 
results were obtained when these analyses were done separately for patients younger or older than 60 years of age 
(Supplementary Fig. S3B).
Validation of the 4-GES in gene expression data sets generated with alternative technolo-
gies. To investigate whether the 4-GES retains prognostic value in AML patients whose samples were analysed 
Data set/cohort Variable
4-GES L-24 M-7 W-3
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
GSE12417/1
GE score, high 
vs. low 3.8 2.3–6.2 8.8 * 10
−08 2.25 1.5–3.4 7.5 * 10−05 na Na na 1.51 1.07–2.14 0.021
Age (years) 1.02 1.0–1.0 0.006 1.03 1.0–1.04 0.0003 na Na na 1.03 1.01–1.04 0.0004
GSE12417/2
GE score, high 
vs. low 4.58 1.1–18.9 0.035 ns ns ns 2.68 1.5–4.9 0.0016 2.01 1.1–3.7 0.022
Age (years) 1.04 1.0–1.1 0.008 ns ns ns 1.03 1.0–1.06 0.0063 1.03 1.0–1.1 0.0079
GSE6891/1
GE score, high 
vs. low 1.69 1.2–2.5 0.008 1.1 0.8–1.6 0.56 2.0 1.4–2.8 5.3 * 10
−05 ns ns ns
Cytogenetic riska 1.91 1.5–2.5 1.4 * 10−06 1.97 1.5–2.6 3.7 * 10−07 1.98 1.6–2.5 2.9 * 10−08 ns ns ns
CEBPAm (w/m/b) 0.79 0.1–6.4 0.828 0.84 0.1–8.1 0.878 0.95 0.1–6.4 0.957 ns ns ns
CEBPAm (yes/no) 0.94 0.0–57.1 0.976 0.71 0.0–61.2 0.878 0.66 0.01–27.5 0.83 ns ns ns
EVI1 expression 
(+/−) 0.82 0.5–1.5 0.511 0.95 0.5–1.7 0.854 0.89 0.5–1.6 0.681 ns ns ns
FLT3-ITD 1.38 0.9–2.0 0.106 1.69 1.2–2.5 0.006 1.82 1.3–2.6 0.0008 ns ns ns
GSE6891/2
GE score, high 
vs. low 2.24 1.5–3.4 0.0001 1.33 0.9–2.0 0.173 1.7 1.1–2.5 0.0086 ns ns ns
Age (years) 1.01 1.0–1.03 0.281 1.01 1.0–1.03 0.128 1.01 1.0–1.03 0.102 ns ns ns
Cytogenetic riska 1.13 0.8–1.6 0.528 1.22 0.9–1.75 0.27 1.35 1.0–1.92 0.092 ns ns ns
EVI1 expression 
(+/−) 3.73 1.8–7.6 0.0002 2.95 1.5–6.0 0.0025 2.9 1.4–5.8 0.0028 ns ns ns
GSE37642
GE score, high 
vs. low 2.13 1.6–2.8 1.8 * 10
−07 1.49 1.2–1.9 0.0016 na Na na ns ns ns
Age (years) 1.03 1.0–1.04 5.6 * 10−12 1.03 1.0–1.04 1.5 * 10−13 na Na na ns ns ns
ELN scoreb 1.26 1.1–1.4 7.1 * 10−05 1.33 1.2–1.5 4.1 * 10−07 na Na na ns ns ns
FAB, M1 vs. others 1.06 0.8–1.4 0.718 0.95 0.7–1.3 0.745 na Na na ns ns ns
FAB, M4 vs. others 1.32 1.0–1.8 0.074 1.45 1.1–2.0 0.017 na Na na ns ns ns
TCGA_LAML
GE score, high 
vs. low 1.52 1.0–2.3 0.051 1.3 0.8–2.1 0.249 ns Ns ns 2.45 1.4–4.3 0.002
Age (years) 1.03 1.0–1.1 0.00013 1.03 1.0–1.1 8.8 * 10−05 ns Ns ns 1.04 1.0–1.1 2.3 * 10−05
Cytogenetic riska 1.29 0.9–1.9 0.179 1.25 0.8–1.9 0.265 ns Ns ns 1.49 1.0–2.1 0.033
Table 3. Multivariable Cox regression analysis for overall survival of AML patients. Parameters provided with 
the respective data sets were first tested in univariable analyses (Supplementary Table S1); those that resulted 
as significant were included in the multivariable models, whose results are summarized in this table. 4-GES, 
4-gene expression score; L-24, 24-gene expression signature by Li et al.16; M-7, 7-gene expression signature 
by Marcucci et al.19; W-3, 3-gene expression signature by Wilop et al.20; HR, hazard ratio; CI, confidence 
interval; GE score, gene expression score; CEBPAm, CEBPA mutation; w, wild type; m, monoallelic; b, biallelic. 
aAssignment to cytogenetic risk groups were included in the respective GEO entries. bAssignment to ELN 
risk groups was provided by T. Herold, University of Munich, Department of Internal Medicine III, Munich, 
Germany. No relevant patient data were provided in GSE71014; therefore, multivariable analyses could not be 
performed. Significant p-values and corresponding HRs and Cis are indicated in bold letters. na, score could 
not be calculated because 2 signature genes were not represented on HG-U133A microarrays; ns, no statistical 
significance found in univariable analyses, thus, no multivariable analyses were performed.
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on platforms other than Affymetrix microarrays, we performed survival analyses on data sets GSE71014 and 
TCGA_LAML2,31. GSE71014 consists of 104 cytogenetically normal AML samples, which were analysed using 
the Illumina BeadArray platform. Forty-eight patients were 4-GESlow and 56 were 4-GEShigh, and the latter had 
significantly shorter OS (adjusted p = 0.02; Fig. 4A). Multivariable analysis was not possible because no additional 
potentially prognostic parameters are provided in this data set.
Data set TCGA_LAML contains RNA-sequencing data from 142 AML samples (76 4-GESlow and 66 4-GEShigh), 
and a high 4-GES was significantly associated with shorter OS (adjusted p = 0.031; Fig. 4B). Multivariable analy-
ses of TCGA_LAML, including the parameters age, cytogenetic risk score, and 4-GES, revealed a HR of 1.52 for 
the 4-GES, however, statistical significance was just not reached (p = 0.051, Table 3).
Overall, these findings demonstrate that the 4-GES is a highly reliable independent prognostic factor in AML.
Comparison of the 4-GES to other prognostic gene expression signatures. As outlined above, 
several gene expression based scores have been proposed for the prognostication of AML. To further validate the 
4-GES, we therefore compared it to a selected subset of these signatures: the 24-gene signature reported by Li et 
al.16 (L-24), the 7-gene signature of Marcucci et al.19 (M-7), and Wilop’s 3-gene signature20 (W-3). The L-24 was 
chosen because it was the first signature that was rigorously validated in several additional data sets and shown 
to be able to refine the ELN score16. The other two signatures were selected because, like the 4-GES, they contain 
<10 genes, making them particularly attractive for potential clinical use. In addition, the L-24 and the M-7 were 
included in a recent comparison of several prognostic scores32 and yielded favourable results. The L-24 and the 
M-7 divide patients into two prognostic groups, while the W-3 is based on three groups. There is no overlap of 
genes between these signatures and the 4-GES (Supplementary Table S3). In univariable analyses, the 4-GES was 
significant in all seven patient cohorts (Supplementary Table S4). The L-24 reached significance in 5/7 cohorts, 
and the M-7 in 4/5 cohorts (in the remaining two cohorts, it was not applicable because not all signature genes 
were represented on the array type used). The W-3 performed well in three cohorts, two of which were used to 
establish it (Supplementary Table S4). In multivariable analyses that included each signature together with all 
other available prognostic parameters, the 4-GES yielded higher hazard ratios than the other signatures in 4/6 
data sets (GSE71014 could not be analyzed because no additional clinical data were provided with it), performed 
similar to the M-7 in one data set, and was superseded by the W-3 in the TCGA data set, which was part of the 
training set used to establish this signature (Table 3). In summary, therefore, the 4-GES compared favourably to 
other prognostic gene expression scores.
SOCS2 promotes AML aggressiveness and stemness. Because the expression of SOCS2 was found 
to be most strongly associated with OS according to the robust likelihood-based approach, and expression dif-
ferences between 4-GESlow and 4-GEShigh AML samples were higher for SOCS2 than for the other genes of the 
model, this gene was subjected to functional analysis. In normal hematopoietic cells SOCS2 levels were high 
in hematopoietic stem cells and substantially decreased during cell differentiation (Supplementary Fig. S4). 
To investigate the role of Socs2 in leukemogenesis, a well-established mouse model of human AML driven by 
the fusion oncogene MLL-AF9 was used33. Transplantation of Lin− Sca-1+ c-Kit+ (LSK) cells transduced with 
pMSCV_MLL-AF9_IRES_Venus34 into sublethally irradiated C57BL/6 recipient mice led to a rapid-onset 
AML-like disease (Supplementary Fig. S5) as reported35. Socs2 mRNA expression was highly up-regulated in 
leukemic cells (LCs) from terminally ill mice compared to normal BM or spleen cells (Fig. 5A). To knock down 
Socs2, LCs were transduced with two different shRNAs (shSocs2 #361 and #362), expressed in the lentiviral vector 
pLKO.1_puro_CMV_TagRFP, or with non-target shRNA (shCtrl) as a control. Venus+ RFP+ cells were isolated 
by flow cytometry, and down-regulation of SOCS2 by the gene specific shRNAs was confirmed by immunoblot 
Figure 2. Validation of the 4-GES in gene expression data set GSE6891, containing cytogenetically 
heterogeneous AML patients. (A) Cohort 1 (N = 222), (B) cohort 2 (N = 185). Kaplan Meier curves for overall 
survival of 4-GESlow (blue) and 4-GEShigh (red) patients are shown. Statistical significance was calculated using 
the log rank test and p-values were adjusted for multiple testing according to Altman et al.58.
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Figure 3. Validation of the 4-GES in gene expression data set GSE37642, consisting of 379 cytogenetically 
heterogeneous AML patients. (A) Cut-off value for stratification of AML patients into 4-GESlow (blue) and 
4-GEShigh (red) was calculated by maximally selected rank statistics. (B) Kaplan Meier curves for overall survival 
of 379 AML patients classified as 4-GESlow (blue) and 4-GEShigh (red). (C) Kaplan Meier curves for overall 
survival of 107 ELN favourable, 174 ELN intermediate I/II and 86 ELN adverse risk AML patients stratified into 
4-GESlow (blue) and 4-GEShigh (red). Statistical significance was calculated using the log rank test and p-values 
were adjusted for multiple testing according to Altman et al.58. (D) Kaplan Meier curves for overall survival of 
AML patients stratified into favourable, intermediate, and adverse based on ELN 2010 classification (left) and 
ELN 2010 + 4-GES classification (right). ELN, European Leukemia Net.
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analysis (Fig. 5B). Knock-down of Socs2 significantly inhibited growth of primary murine LCs in vitro (Fig. 5C), 
and delayed disease onset upon transplantation into C57BL/6 recipient mice (Fig. 5D). In LCs from terminally ill 
mice, it effected a shift from immature (Mac-1+ Gr-1−) to more mature (Mac-1+ Gr-1+) myeloid cells (Fig. 5E). 
Moreover, experimental down-regulation of Socs2 negatively affected the abundance and functional properties of 
LSCs. In the MLL-AF9 model, LSCs are strongly enriched in the Lin− Sca1− c-Kit+ CD34+ CD16/CD32hi popula-
tion35, henceforth termed LSCe. Knock-down of Socs2 caused a decrease of immunophenotypically defined LSCe 
among Venus+ RFP+ LCs (Fig. 5F), lessened the number of quiescent LSCe (Fig. 5G), and reduced clonogenicity 
in a serial replating assay (Fig. 5H), indicating that Socs2 enhanced LSC abundance and function in the MLL-AF9 
mouse model of AML.
To confirm these observations, a second AML mouse model driven by the combined action of a Flt3 gene 
with an activating internal tandem duplication (Flt3-ITD) and a mutated nucleophosmin gene (NPM1c) was 
employed36. As with the MLL-AF9 model, spleen cells from terminally ill Flt3-ITD/NPM1c mice expressed highly 
elevated levels of Socs2 mRNA compared to normal spleen cells (Supplementary Fig. S6A). Knock-down of Socs2 
in Flt3-ITD/NPM1c LCs led to a rapid and complete loss of RFP+ cells in culture (Supplementary Fig. S6B). 
While this prevented the use of these cells for transplantation experiments, it provided strong evidence for an 
essential role of Socs2 in the proliferation and/or survival of Flt3-ITD/NPM1c driven LCs. Noteworthy, analyses of 
expression microarray data from sorafenib or DMSO treated murine pro-B cells with stable FLT3-ITD expression 
revealed significantly lower expression of Socs2, Il2ra and Phgdh in sorafenib treated cells compared to DMSO 
controls (Supplementary Fig. S7). Further confirming the role of SOCS2 in leukemic cell proliferation, retroviral 
expression of this gene in the malignant human myeloid cell lines U937 and HL60 caused significant increases in 
cell numbers compared to empty vector transduced cells (Supplementary Fig. S8).
Discussion
Several prognostic gene expression signatures for AML patients have been reported, but were established based 
on a priori assumptions about the identity of the potentially relevant genes, and/or contained relatively large num-
bers of genes, making them too complex for potential clinical applications7,12–20. We therefore aimed to establish 
a signature composed of a small number of genes, both whose identity and number were determined through 
unbiased approaches. As a training set, a cohort of cytogenetically normal patients representing all age groups 
was used. The resulting signature, 4-GES (consisting of SOCS2, IL2RA, NPDC1, and PHGDH) was confirmed as 
an independent prognostic parameter in five of six additional data sets, including some that contained cytogenet-
ically heterogeneous patient groups and/or employed different gene expression profiling technologies, and just 
fell short of significance in the sixth data set. When the 4-GES was applied to distinct cytogenetic subgroups of 
AML a highly significant prognostic value was observed for the cytogenetically intermediate subgroup, however, 
for the cytogenetically poor subgroup statistical significance was not reached after correction for multiple testing. 
Because the cytogenetically poor subgroup was rather small, the 4-GES should be evaluated in a much broader 
cohort of adverse cytogenetic risk AML patients in future studies. The 4-GES performed as well or better than 
other rigorously tested prognostic signatures, and was able to substantially refine the ELN classification both in 
younger (<60 years) and older (≥60 years) patients with AML. Further studies are necessary to develop a stand-
ardized, fast and easy to use (multiplex) real-time PCR approach for the 4 genes and housekeepers to stratify AML 
patients into low and high risk groups prospectively.
At present, risk stratification in AML is based on recurrent genetic alterations. In addition to their prognostic 
value, these contribute to various aspects of disease pathology, and some of them have been developed as thera-
peutic targets2–6,37. Some genes whose individual aberrant expression had prognostic significance in AML were 
also shown to contribute to leukemogenesis9,10, and in a recent report, a gene expression signature associated 
with LSCs and poor therapy response was used to identify targeted drugs potentially useful for the treatment 
Figure 4. Validation of the 4-GES in the gene expression data sets (A) GSE71014 and (B) TCGA_LAML. 
Kaplan Meier curves for overall survival of 4-GESlow (blue) and 4-GEShigh (red) patients are shown. Statistical 
significance was calculated using the log rank test and p-values were adjusted for multiple testing according to 
Altman et al.58.
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of AML8. The 4-GES comprises only four genes, making it appear likely that most or all of these also make a 
functional contribution to AML pathogenesis. To begin to address this question, the role of SOCS2 in AML was 
investigated using suitable experimental models. SOCS2 was selected because it resulted as the top gene from the 
survival modeling approach; in addition, it was strongly and significantly up-regulated at relapse of AML, a dis-
ease stage that is often refractory to therapy and thus can be considered as inherently aggressive38. SOCS genes are 
transcriptional targets of activated JAK-STAT signalling22, a pathway that plays a major pro-leukemogenic role 
Figure 5. Effects of Socs2 knock-down in an MLL-AF9 driven mouse model of AML. (A) Socs2 mRNA 
levels in MLL-AF9+ BM LCs and in BM and spleen cells of healthy mice were determined by qRT-PCR and 
normalised to those of the housekeeping gene ß-2-microglobulin using the ∆∆CT method. Mean ± SEM of three 
independent experiments; ***p < 0.001 (Student’s two-tailed t-test). (B) Left panel, immunoblot analysis for 
SOCS2 expression in shCtrl or shSocs2 transduced MLL-AF9+ LCs. Right panel, quantification of immunoblot 
results; mean ± SEM of two independent experiments; *p < 0.05 (Student’s two-tailed t-test). (C) shCtrl or 
shSocs2 transduced MLL-AF9+ LCs were maintained in suspension culture and counted on the indicated 
days. Mean ± SEM of three independent experiments. **p < 0.01; ***p < 0.001 (2-way ANOVA followed by 
Bonferroni’s post-hoc test). (D) Kaplan-Meier plot of mice transplanted with shCtrl or shSocs2 transduced 
MLL-AF9+ LCs (300.000 Venus+ RFP+ cells per mouse, n = 4). **p < 0.01 (log-rank test). (E–H) Analyses 
of LCs from mice terminally ill after transplantation with shCtrl or shSocs2 transduced MLL-AF9+ LCs. 
Mean ± SEM of 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 (2-way ANOVA followed by 
Bonferroni’s post-hoc test). (E) Myeloid differentiation of spleen LCs. Mac-1+ Gr-1−, immature LCs; Mac-1+ 
Gr-1+, mature LCs. (F) Abundance of LSC enriched cells (LSCe; Lin− cKit+ Sca-1− CD34+ CD16/CD32hi cells) 
among Venus+ RFP+ spleen LCs. (G) Cell cycle distribution of spleen LSCe was determined by Ki67 and DAPI 
staining. Quiescent cells were defined as Ki67− cells with a 2n DNA content. (H) Colony formation by BM LCs 
serially plated into methyl cellulose.
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in AML, contributes to the growth and maintenance of AML LSCs29, and is being explored as target for rationally 
designed therapeutics39. SOCS proteins act as substrate recruiting components of E3-ubiquitin ligase complexes 
and initiate the degradation of cytokine receptors and signaling proteins, thus acting as negative feedback regu-
lators of the cytokine activated pathways leading to their induction22. They would therefore be expected to serve 
as tumor suppressors, and SOCS2 was indeed down-regulated in several cancer types22. In contrast, SOCS2 was 
up-regulated in AML compared to healthy controls, and particularly in samples with activating ITD mutations 
of the tyrosine kinase receptor FLT340. SOCS2 promoted the degradation of activated FLT3, and decreased pro-
liferation and colony formation of cells experimentally expressing FLT3-ITD40; however, these experiments were 
performed using the murine pro-B cell line Ba/F3, which may not be an ideal model for human AML. In contrast, 
the data reported here show that experimental expression of SOCS2 had a small but significant growth promoting 
effect in malignant human myeloid cell lines (Supplementary Fig. S8). Correspondingly, its knock-down in pri-
mary cells from the Flt3-ITD/NPM1c driven model of cytogenetically normal AML retarded proliferation and/or 
promoted cell death or senescence to an extent that precluded further experimentation (Supplementary Fig. S6B). 
A comparable, albeit less dramatic effect was observed with cells from an MLL-AF9 driven AML model (Fig. 5C). 
In this model, knock-down of Socs2 also decelerated leukemia onset in mice, promoted LC differentiation, and 
reduced the abundance, quiescence, and activity of LSCs (Fig. 5D–H), the LC subpopulation that acts as driver of 
the disease and is responsible for therapy resistance and relapse1. Together with the observation that high SOCS2 
expression is associated with a poor prognosis (Supplementary Fig. S1), these data provide strong support for 
an oncogenic role of this gene in AML. This may reflect a role of SOCS2 not only as a negative regulator of the 
JAK-STAT pathway, but also as a downstream target of it. Oncogenic roles of SOCS2 were also reported in other 
tumor entities: SOCS2 levels were elevated in colon and prostate cancer, and high SOCS2 expression was asso-
ciated with a poor prognosis in the latter23,24. The transcription of SOCS2 was repressed by wild type p53, and it 
promoted proliferation, anchorage independent growth, resistance against basal and drug induced apoptosis, and 
tumor growth in xenograft assays in prostate and colon cancer cell lines23–25. Because our data regarding Socs2 
expression and growth regulatory effects of Socs2 derived from TP53 wt mice/cells and TP53 mutant human mye-
loid cells, we suggest that these effects are independent of p53 and TP53 mutations in AML. Other examples of a 
negative signalling regulator associated with poor prognosis include the dual-specificity phosphatase 6 (DUSP6) 
which regulates the basal levels of phosphorylated ERK in the cytosol41,42. High DUSP6 expression was found to 
be associated with poor survival in ALL and breast cancer patients43,44.
As for the other genes in the 4-GES, the interleukin 2 receptor subunit alpha (IL2RA, also named CD25) gene 
was specifically expressed on LSCs in a subset of patients with AML45, and was previously reported as an inde-
pendent prognostic parameter able to further improve prognostication based on cytogenetic and mutational 
data46. An ongoing phase I study of patients with relapsed/refractory CD25-positive AML/ALL treated with the 
human monoclonal anti-CD25 antibody ADCT-301 (NCT02588092) showed an acceptable safety profile. Data 
about treatment response are not available yet47. However, an other trial (NCT02432235) tested efficacy of ADCT-
301 in relapsed/refractory Hodgkin/Non-Hodgkin lymphoma patients and reported an overall response rate of 
56%48.
The neural proliferation, differentiation and control 1 (NPDC1) gene was cloned as a gene associated with 
contact inhibition of neuronal precursor cells49. It is one of the less intensely studied genes, but, interestingly, was 
significantly up-regulated at relapse of AML38.
Phosphoglycerate dehydrogenase (PHGDH) catalyzes the rate limiting step of serine synthesis from the glyco-
lytic intermediate 3-phosphoglycerate; serine metabolism plays roles in both nucleotide biosynthesis and antiox-
idant defense. PHGDH is overexpressed in triple negative breast cancer, lung adenocarcinoma, and other tumors, 
and is associated with a poor prognosis. It contributes to tumor formation, stemness, metastasis, and chemother-
apy resistance50,51, and is actively pursued as a therapeutic target52,53. Its role is far less well studied in leukemia, 
but serine deprivation and PHGDH inhibition were reported to cooperate to inhibit growth of the malignant 
human myeloid cell line HL6054.
In summary, we present here a gene expression signature (4-GES) that is a highly significant independent 
prognostic parameter throughout several independent AML cohorts. A major advantage over previously pub-
lished signatures is that it is composed of only four genes, which makes its application in routine diagnostics 
feasible. Moreover, the 4-GES has the potential to refine the ELN classification, which is the current state of the art 
risk classification of AML. This refinement was associated with re-assignment of substantial numbers of patients 
into the prognostically poor subgroup. However, as outlined above, the genes constituting the 4-GES are likely to 
contribute to the pathological features of AML, raising the possibility that the 4-GES may not only be a prognosti-
cator of poor outcome under standard therapy, but even represent a target for rationally designed therapies maybe 
improving outcome of the subgroup of AML that currently has the poorest prognosis.
Materials and Methods
Publicly available gene expression data sets. Four independent microarray data sets, 2 of which 
consist of 2 cohorts each, were obtained from the Gene Expression Omnibus (GEO) database, and The Cancer 
Genome Atlas (TCGA) RNA-seq data were downloaded from the Cancer Browser database (Table 1). For 
GSE37642, risk classification according to the ELN 2010 score was kindly provided by T. Herold, University of 
Munich, Department of Internal Medicine III, Munich, Germany. All samples with French American British 
(FAB) type M3, which mandates a substantially different treatment protocol than used for all other AML patients, 
and samples with unknown FAB type or myelodysplastic syndrome (MDS) were excluded. To optimize compa-
rability among the microarray data sets, raw Affymetrix data were processed, normalised and log2 transformed 
using the frozen robust multiarray (fRMA) algorithm and R 3.4.2 software55. Pre-processed Illumina BeadArray 
data (GSE71014) and RNA-seq data (TCGA_LAML) were used as provided by the databases. Microarray data of 
DMSO/sorafenib treated Ba/F3-ITD cells and of human hematopoietic cells were obtained from ArrayExpress 
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database (E-MTAB-4487, E-MEXP-1242) and GEO database (GSE42519, GSE17054, GSE19599, GSE11864). 
Heatmaps were generated on scaled log2 values using ClustVis56.
Prognostic model selection and survival analyses. A prognostic gene expression signature was calcu-
lated by applying rbsurv, a robust likelihood-based survival modeling approach57, to cohort 1 of GSE12417. The 
samples in this data set were randomly distributed between a training and a validation set. Each gene was fitted 
to the training set and the parameter estimate for the association between expression of this gene and overall 
survival (OS) was calculated. With the parameter estimate, log likelihood to predict OS was evaluated in the 
validation set. This procedure was repeated 100 times, yielding 100 log-likelihoods per gene. The gene with the 
largest mean log likelihood (SOCS2) in the survival model was selected as the first top gene. By evaluating all 
possible two-gene models, the gene that together with SOCS2 yielded the largest mean log likelihood was selected 
as the second top gene. This forward gene selection process was continued and resulted in a set of candidate 
genes for the prognostic model. Finally, an optimal prognostic model was selected based on the minimal Akaike 
information criterion (AIC) which takes the goodness of the model fit and the complexity (number of genes) into 
account.
For each patient in a data set, a score was calculated as the sum of the products of log2 transformed expression 
values of the model genes and their β-coefficients from a multivariable Cox regression, which was performed on 
cohort 1 of data set GSE12417 and included all genes. Optimal cut-offs for classification of patients into high-risk 
or low-risk groups were calculated for each data set using maximally selected rank statistics (R package maxstat). 
The Kaplan Meier method was used to estimate survival distributions and the log-rank test was used to evaluate 
statistical significance in OS between risk groups. P-values from these analyses were adjusted for multiple testing 
as described previously58. Uni- and multivariable Cox regressions were calculated using the coxph function in 
R. Univariate analyses were performed for all parameters provided along with the respective gene expression 
data (Supplementary Table S1). Only parameters which were significant in univariate analyses were included in 
multivariable analyses. A p-value of <0.05 was considered statistically significant. The R packages survival and 
survminer were used for these calculations and for data visualization. All statistical tests were performed using 
R 3.4.2.
Ethics statement. Animal experiments were approved by the Animal Ethics Committee of the Medical 
University of Vienna and the Austrian Federal Ministry of Education, Science, and Research (GZ66.009/0309-WF/
V/3b/2015). Federation of European Laboratory Animal Science Associations guidelines to minimize animal 
distress and suffering were followed.
Isolation, culture, transduction, and transplantation of primary murine cells. The packaging cell 
lines Platinum-E (PlatE) and Phoenix-GP were maintained in DMEM (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen) and 1% Penicillin/Streptomycin (Sigma-Aldrich). Primary murine hematopoi-
etic or leukemic cells (LCs) were cultured in IMDM medium (Thermo Fisher Scientific) containing 10% FBS, 
1% L-Glutamine (Thermo Fisher Scientific), 50 ng/ml mSCF, 10 ng/ml mIL-3, 10 ng/ml mTPO, 10 ng/ml mFlt3L 
(all from Peprotech), and 10 ng/ml mIL-6 (Biolegend). To generate mice with MLL-AF9 driven AML, a retro-
viral transduction/transplantation approach was used. Lin− Sca-1+ c-Kit+ (LSK) cells were isolated from bone 
marrow (BM) of 6–8 week old C57BL/6 mice (Department of Laboratory Animal Science & Genetics, Himberg, 
Austria). Retroviral particles were produced by calcium phosphate mediated co-transfection of PlatE cells with 
pMSCV_MLL-AF9_IRES_Venus34 (kindly provided by Dr. Johannes Zuber, Research Institute of Molecular 
Pathology, Vienna, Austria) and the ecotropic packaging plasmid psi2 (gag, pol, env). LSK cells (100,000 cells in 
500 µl culture medium) were spinoculated with 1500 µl retroviral supernatant in the presence of 4 µg/ml poly-
brene (Sigma-Aldrich) and cytokines (as in the culture medium) for 1 h at 1300 rpm and 32 °C in a 12-well plate 
precoated with Retronectin (Takara). The infection was repeated with new retroviral supernatant after 5, 10, and 
24 h, followed by a 48 h incubation in culture medium.
To knock down Socs2, two validated Socs2 shRNAs (shSocs2 #361 and #362) and a non-target control shRNA 
(SHC012) in pLKO.1_puro_CMV_TagRFP (Mission© library, Sigma-Aldrich) were transfected into Phoenix-GP 
cells, along with the packaging plasmids pSPAX2 and pMDG.2, using calcium phosphate precipitation. Lentiviral 
particles were harvested after 48–72 h and used for spinoculation of spleen cells from mice with MLL-AF9 or 
FLT3-ITD/NPM1c36 driven AML as described above. The infection was repeated with fresh lentiviral superna-
tant after 24 h. Three days later, fluorescence marker positive cells were sorted and used for in vitro assays and/or 
transplantation of recipient mice.
For transplantation, 6–8 week old female C57BL/6 recipient mice were sub-lethally irradiated (5 Gy), anaes-
thesized on the next day, and injected retro-orbitally with MLL-AF9-transduced LSK cells (160,000 cell/mouse; 
unsorted because of the strong selective advantage associated with MLL-AF9 expression) or with shCtrl or 
shSocs2-transduced MLL-AF9+ LCs (300,000 Venus+ RFP+ cells/mouse). BM and spleen cells were harvested 
from terminally ill mice for use in downstream experiments.
Flow cytometric assays to analyse LC differentiation and the abundance and quiescence of LSC 
enriched cells. To analyze the differentiation status of LCs, spleen cells from terminally ill mice were stained 
with fluorophor labelled antibodies against Gr-1 and Mac-1 (Supplementary Table S2) for 30 minutes on ice, 
washed once with staining buffer, and subjected to flow cytometry.
In the MLL-AF9 AML model, LSCs are highly enriched in the Lin− Sca1− c-Kit+ CD34+ CD16/CD32hi pop-
ulation35,59; we therefore defined Venus+ RFP+ cells with this immunophenotype as LSC enriched cells (LSCe). 
LSCe abundance among Venus+ RFP+ LCs was determined by flow cytometric analysis of leukemic spleen cells 
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stained with the respective antibodies (Supplementary Table S2). To determine the proportion of quiescent LSCe, 
spleen cells from leukemic mice were stained with antibodies against LSCe surface markers, fixed and permea-
bilised in Cytofix/Cytoperm (BD Biosciences), stained with Ki-67 antibody (Supplementary Table S2) and DAPI 
(1 µg/mL; Sigma-Aldrich) in Perm/Wash™ Buffer (BD Biosciences), washed with Perm/Wash™ Buffer, and sub-
jected to flow cytometry. Ki-67− LSCe with a 2n DNA content were considered quiescent.
Flow cytometric analyses were performed on an LSR Fortessa SORP (BD Biosciences), and data were analysed 
with FlowJoX software (Treestar).
Colony formation assay. BM cells from leukemic mice were sorted for Venus+ RFP+ positivity, and 2,000 
cells from each genotype were seeded into methyl cellulose (MethoCult GF M3434; Stem Cell Technologies). 
Total colony formation was quantified after 7 days, and 2,000 cells per condition were used for replating.
Quantitative RT-PCR. Total RNA was extracted using Trizol (Life Technologies) and reverse tran-
scribed using random hexamer primers (Life Technologies) and M-MLV reverse transcriptase (Life 
Technologies). Quantitative RT-PCR (qRT-PCR) was performed on a Step One Plus Real Time PCR sys-
tem (Life Technologies) using GoTaq qPCR Master Mix (Promega) and the following primers: Socs2 (fwd: 
5′-CTGCGCGAGCTCAGTCAAA-3′, rev: 5′-CAATCCGCAGGTTAGTCGGT-3′), ß-2-microglobulin (fwd: 
5′_CCTTCAGCAAGGACTGGTCT-3′, rev: 5′-TGTCTCGATCCCAGTAGACG-3′). Assays were performed in 
triplicate, and Socs2 expression was normalised to ß-2-microglobulin expression using the ΔΔCT method60.
Immunoblot analysis. Preparation of protein lysates, SDS-PAGE, transfer to PVDF membranes (Hybond-P; 
Amersham), and antibody incubations were performed using standard procedures. Blots were developed using 
SuperSignal West Femto or Pico Chemiluminescent Substrate (both from Thermo Scientific) and scanned using 
a ChemiDoc Touch Imaging System (Bio Rad). Densitometric analysis was performed with Image-J software 
(National Institutes of Health, Maryland, USA).
Statistical analyses of experimental data. Differences between two independent groups were calcu-
lated using Student’s t-test, and differences between multiple groups were determined by 2-way ANOVA fol-
lowed by Bonferroni’s post-hoc test. The log-rank test was used to evaluate survival differences between groups of 
mice. p-values < 0.05 were considered statistically significant. Analyses were performed using GraphPad Prism 
6 software.
Ethics approval. Animal experiments were approved by the Animal Ethics Committee of the Medical 
University of Vienna and the Austrian Federal Ministry of Education, Science, and Research (GZ66.009/0309-WF/
V/3b/2015). Federation of European Laboratory Animal Science Associations guidelines to minimize animal 
distress and suffering were followed.
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